TMC
RXRX icon

Themes Management Co’s Recursion Pharmaceuticals RXRX Stock Holding History

Themes Management Co’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Sell
69,782
-7,218
-9% -$24K 0.17% 105
2026
Q1 		$236K Buy
+77,000
New +$298K 0.15% 128

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Themes Management Co's RXRX Position: Q2 2026 in Review

Themes Management Co reduced its Recursion Pharmaceuticals (RXRX) stake by 9.4% in Q2 2026, selling an estimated $24K and leaving 69,782 shares worth $256K. The position accounts for 0.17% of the portfolio, ranked #105.

Themes Management Co first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Themes Management Co held 69,782 shares of Recursion Pharmaceuticals worth $256K as of Q2 2026.
  • Themes Management Co sold 7,218 Recursion Pharmaceuticals shares in Q2 2026, an estimated $24K.
  • Recursion Pharmaceuticals made up 0.17% of Themes Management Co's portfolio in Q2 2026, its #105 holding.
  • Themes Management Co first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Themes Management Co's 13F filing for Q2 2026, filed 21 Jul 2026.